Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas3.79 B4.36 B4.52 B5.19 B5.98 B6.89 B7.07 BPesquisa e desenvolvimento1.14 B1.2 B1.32 B1.41 B1.61 B2.05 B2.13 BLucro operacional-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BLucro não operacional, total1 M-123 M-508 M-358 M-407 M-96 M267 MDespesa com juros, líquida de juros capitalizados361 M341 M470 M265 M305 M349 M357 MReceitas não operacionais, líquidas das despesas com juros-722 M-682 M-940 M-530 M-391 M-217 M-39 MReceitas/despesas incomuns362 M218 M-38 M-93 M-321 M-228 M-51 MLucro antes dos impostos-79 M1.08 B1.14 B1.99 B2.28 B3.38 B3.74 BParticipação no lucro———————Impostos2 M36 M443 M393 M436 M493 M184 MParticipação de minoritários———1 M-8 M-6 M-6 MOutras receitas/despesas após impostos———————Lucro líquido antes das operações descontinuadas-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BOperações descontinuadas———————Lucro líquido-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas-115 M985 M642 M1.57 B1.85 B2.9 B3.56 BLucro básico por ação-0.080.690.451.081.261.962.4Lucro diluído por ação-0.080.690.451.071.251.942.39Número médio de ações básicas1.42 B1.42 B1.43 B1.45 B1.47 B1.48 B—Ações diluídas1.42 B1.43 B1.44 B1.46 B1.49 B1.49 B—EBITDA1.04 B2.29 B2.78 B3.54 B3.87 B4.98 B5.18 BEBIT-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BCusto da receita3.46 B3.71 B3.96 B4.34 B5.26 B6.22 B6.36 BOutros componentes do custo149 M——————Amortização e depreciação (fluxo de caixa)1.12 B1.09 B1.14 B1.2 B1.27 B1.37 B1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.